Graphic: Leza Berardone Everybody wants a piece of the pie, especially when that pie is worth $206 billion. That is the total amount the states won from the tobacco companies last November in the largest civil settlement in U.S. history. Florida, Minnesota, Mississippi, and Texas had settled individually for a combined amount of $40 billion earlier. The payments will be made over the next 25 years, and even though the money is still not available to the states, a scramble over how to spend it is
 Graphic: Leza Berardone |
Initially, many legislators were concerned that the federal government might attempt to recoup some of the states' tobacco settlement by claiming the payments from the tobacco companies were essentially third-party Medicaid reimbursements. However, in late May of this year President Bill Clinton signed a bill with an amendment that denies the federal government access to any of the money. With the recoupment ...
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.
View this Issue
Explore how blood-based biomarkers perform across Alzheimer’s disease stages, including AIBL Study findings comparing p-Tau217 and other markers against amyloid-beta and tau PET reference standards.
Learn how microvolume UV/Vis and DLS can accelerate, automate, and streamline protein developability screening while reducing sample requirements.
Assess protein sample purity and homogeneity in minutes with mass photometry using only nanograms of sample.
Explore how super-resolution microscopy enables particle-level characterization of lipid nanoparticle composition, cargo loading, heterogeneity, and stability, providing complementary insights for formulation development and optimization.
The placements follow the commercial launch of Pyxa at the Advances in Genome Biology and Technology (AGBT) meeting in February 2026 and mark the company's transition from Early Access into global commercial availability.
The CellRaft AIR streamlines antibody discovery with imaging, functional screening, and gentle isolation of viable single B cells and hybridomas, helping verify monoclonality and identify high producing clones faster.
Load plasma directly into prefilled cartridges, no pretreatment, no ethanol. Under 30 minutes of instrument run time, up to 48 samples in parallel, with a high-throughput format also available.
Two Paige tools, powered by the Virchow pathology foundation model, are now available within a single image management workspace for oncology research.
